Plus Therapeutics(US:PSTV) Globenewswire·2025-12-01 12:30Core Insights - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, with an abstract accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium [1][2] Group 1: Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and specializes in targeted radiotherapeutics aimed at difficult-to-treat CNS cancers, aiming to enhance clinical outcomes [6][7] - The company is advancing a pipeline of product candidates, particularly in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) [7] Group 2: Product Information - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [4] - REYOBIQ is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions [4] Group 3: Clinical Context - Leptomeningeal metastases (LM) occur in approximately 5% of patients with metastatic cancer, with a median survival of 2-6 months, indicating a critical need for effective treatment options [3] - The CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, develops tests to identify tumor cells that have metastasized to the CNS, enhancing patient management for those with LM [5]